Table 4.
Subgroup analysis of pooled CRT means (95% confidence intervals) in µm
| 6 months | ||||||
| Previous anti-VEGF injections (n) | <12 injections −52.20 (−104.60 to 0.10) |
≥12 injections −66.10 (−86.60 to −45.50) | ||||
| Aflibercept injections (n) | <4 injections −66.90 (−114.00 to −19.90) |
≥4 injections −63.10 (−85.00 to −41.10) |
||||
| Dosing | Loading + 2q8 −44.20 (−85.80 to −2.60) |
Loading + PRN −103.20 (−173.60 to −32.80) |
Loading + T&E −38.40 (−70.40 to −6.30) |
2q8 −62.50 (−117.60 to −7.40) |
PRN −75.10 (−132.00 to −18.20) |
T&E −47.50 (−106.80 to 11.80) |
| Study design | Prospective −70.00 (−107.80 to −32.10) |
Retrospective −58.30 (−75.00 to −41.50) |
||||
| 12 months | ||||||
| Aflibercept injections (n) | <8 injections −49.00 (−63.20 to −34.80) |
≥8 injections −53.20 (−100.10 to −6.20) |
||||
| Dosing | Loading + 2q8 −25.90 (−40.50 to 11.30) |
Loading + PRN −95.40 (−136.30 to −54.50) |
Loading + T&E −24.00 (−27.60 to −20.30) |
2q8 −69.40 (−142.50 to 3.70) |
PRN −53.00 (−90.70 to −15.20) |
|
| Study design | Prospective −85.00 (−119.30 to −50.70) |
Retrospective −38.80 (−53.10 to −24.60) |
||||
Note: n represents number, and 2q8 represents bimonthly injections.
Abbreviations: CRT, central retinal thickness; PRN, pro re nata; T&E, treat and extend; VEGF, vascular endothelial growth factor.